Company intelligence / Profile preview

APAC Biotech

Gurgaon, Haryana, India

Ownership: Private
Employees: ~11
Development stage: Other

Overview

APAC Biotech's APCEDEN is the first India-approved dendritic cell-based cancer immunotherapy, with clinical data supporting an immune-activating, personalized approach for advanced cancer patients. It has received post-marketing study approval from Indian FDA and is expanding into brain cancer (GBM) and pancreatic cancer (PDAC) research[1][4].

Therapeutic areas: Oncology
Modalities: Dendritic cell therapyCell therapyBiologic
Industry: Biotech

Drug pipeline

2 assets

APCEDEN

Unknown

1 more asset in the full pipeline.

Request access →

Partnerships

Sir Ganga Ram Hospital (Delhi)Apollo Hospital Indraprastha (Delhi)Medanta Medicity Hospital (Gurugram)Ruby Hall Clinic (Pune)HCG Hospital (Bengaluru)Fortis Hospital (Mohali)Vrinchi Hospital (Hyderabad)Apollo Hospital (Hyderabad)Bhagwan Mahavir Hospital (Jaipur)

Beyond the preview

Go deeper on APAC Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APAC Biotech.

Explore the full profile